Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My thoughts are something aligned with onemind and gemini program,
Most likely same group that brought myself and a few others(zoomb). I stuck to me dd and have been averaging down as well over past year. Future looks bright..
Look back at gc's blog after first summit last year.. Sorry cant post link right now.
I'm hoping to hear more tomorrow about those initiated conversations ect he spoke of in that blog. Glta
Summit begins tomorrow at 8:00am EST. Looking forward to hearing what is to be said about TBI/Amarantus/Lympro perhaps even before the bell.
So "this" is why news was quiet over the holidays..:)
https://www.facebook.com/photo.php?fbid=10100892416187603&set=a.10100892416212553.1073741825.201749&type=1&theater
Correction... Christopher A. Seeger, Seeger Weiss LLP(Plaintiffs' Co-Lead Counsel in NFL Concussion Litigation)
Added to the list of presenters, not listed as supporting partner. My mistake.
Also of interest today is an added Supporting Partner of the #C4CT Concussion Awareness Summit.
Seeger Weiss LLP-Christopher A. Seeger
Plaintiffs' Co-Lead Counsel in NFL Concussion Litigation
Sure, he may be there to pick up a few more former-NFL clients, but still a great addition to the public visibility of this summit.
I believe that challenge I was specifically for diagnostic.
Challenge II has entry deadline in a few weeks. It is more geared towards protection and treatment of tbi.
"We believe now, more than ever, that we have a film on our hands that will reach both major and independent markets and will be screened by viewers from every corner of the globe."Jocelyn Leroux (Producer/Director)-update on status of "A Light in the Shadows" – A Feature Documentary outlining Wolfram's Syndrome and research being done by Dr. Urano at U. Massachusetts Med.
http://www.wolframmovie.com/in-production
Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
http://ir.stockpr.com/amarantus/company-news/detail/1024/amarantus-licenses-manf-related-wolframs-and-diabetes-therapeutic-and-diagnostic-intellectual-property-from-university-of-massachusetts-medical-school
Interesting background of Andrea Kremer, the NFL Network representative who is attending, and participating in, the #C4CT Summit.
Q/A with Andrea Kremer: Why NFL Network hired her to cover league’s most controversial issue: player safety
http://www.shermanreport.com/qa-andrea-kremer-why-nfl-network-hired-cover-leagues-controversial-issue-player-safety/
Interesting new twitter link from Fumihiko Urano
https://twitter.com/search?q=Fumihiko%20Urano&src=typd
"Endoplasmic Reticulum: An Interface Between the Immune System and Metabolism"
http://diabetes.diabetesjournals.org/content/63/1/48.long
Bummer, if only there was something that has been shown to provide protection against ER stress...
Have to ask.. Its not like you to be so vague. What do you mean by "information in signatures"?
Biggest name to me in today's PR may be Andrea Kremer of the NFL Network. Although the Summit is "during" the NFL Super Bowl Week.... I don't recall there being a true indication that current National Football League had anything to do with the Summit, correct?
Still doesn't, but sending someone from the NFL Network may be a step towards this. Regardless, it acknowledges the Summit by the NFL and could lead to true "NFL Week" coverage. GLTA
I understand your posting, but wasn't the purpose the Amended S-1a's to push this effective date.
If DocStock is correct the 20 period available for the >.10 run may not have even come to pass yet.
He had suggested contacting Marcele for clarification.
Jeff Fessler, Esq.
Marcelle S. Balcombe, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10006
Telephone: (212) 930-9700
Fax: (212) 930-9725
Per 12/13 S-1a
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.
Thanks for the clarification..
To each there own. I don't recall anyone even being mentioned besides Marcelle, but perhaps Doc had a reason for self-editing.
Me, I'm still sitting just as confidently as ever so thanks Doc.
Check posts 92271 and 92275. Mods can "edit posts." Someone PM Docstock12 to see if his recent post said just "Go ambs."
Wasnt there a few brief words just this morning/hesterday between jo and another mod mentioning the editing ?
Taht would be my guess. That one simple post....now cleared makes all of this gloom and doom bs go away..
According to DokStocks post #92482.... he spoke with someone(Marcelle) that confirmed that the finalizing of the warrents is not complete but should be soon. Clock would begin then.
My question is why when I looked back at his post...it now reads blankly
"Go AMBS"
Look over DocStocks past posts. Very doubtfull this was his words. Someone edited his very informative post.
He stated that the 20 day period above .10 hasnt even started yet. Debentures haven't been declared effective yet. Should be within "two weeks max"-Marcelle
Then the 20 day period for the warrents will begin.
Per DocStock12.
Just me or did DocStock's informative post just get edited??
So CPT code = commercialization?? Or just a step closer to it?
So, then every day closer to the target of 20 days should tighten the screws on anyone bringing deals to the table to meet Gerald’s expectations. Today is one day closer...
Dilutive funding or not, existence of the warrants represent that Amarantus isn't completely desperate and doesn't need to settle for a less than worthy offer. The closer we are to standing alone, the sweeter the deals should become.
For clarification, is it 20 days of "some trading" above the .10 mark, or the the pps must remain above the .10 mark for warrants?
Also interesting that I'm assuming that Gerald and father are perhaps choosing to attend this IBIS partners award ceremony rather than present at the BioTech Showcase.Perhaps siginificant..
"A Company representative" will present at Biotech Showcase on Wednesday, January 15, 2014 at 4:00 PM PST at the Parc 55 Wyndham Hotel. This presentation may be viewed live and will by archived at http://www.media-server.com/m/p/i98tbt59.
Pure speculation(and possibly complete BS) and dot connecting for fun...
"We invest in promising new drugs, medical devices and medical tools from Stage II clinical trials and beyond up and through product approvals, commercialization, manufacturing and distribution through our Accelerator Program. We are keenly interested in biologics and experimental applications for difficult to treat diseases such as cancer, sickle cell anemia, and rheumatoid arthritis, as well as devices that ease drug delivery for chronic conditions such as diabetes and kidney disease or tools that enable new surgical procedures. We work with top intellectual property attorneys and specialist to gain the broadest patent protection possible."
Per IBIS Partners site. Creators of the Innovation and Equity 50 most...
"Templeton, chief economist for the Ibis Partners hedge fund based in West Palm Beach, is organizing a $100 million private equity pool to support a number of ready to launch technologies developed by 50 Most selectees and participants"
Commissiongs are "2" of the "50".
http://www.ibispartners.com/biotechnology.html
Hmm, if only Amarantus had a phase 2 candidate....<sarcasm>
Another possible investor/funding opportunity in 50 most important african-americans in technology
http://www.souloftechnology.com/50-most.html
Check the list of others on the link....not a bad group to be associated with.
Per site info, "Another objective is to awaken investment in these critical industrial pioneers, some with as many as 100 patents. Templeton, chief economist for the Ibis Partners hedge fund based in West Palm Beach, is organizing a $100 million private equity pool to support a number of ready to launch technologies developed by 50 Most selectees and participants in the companion Catapulting Innovation Showcase held for the past three years.During the symposium, companies like Amarantus BioSciences of San Francisco will present their transformational discoveries. Dr. John Commissiong, chief scientific officer, will tell the clinical progress of its smart protein MANF for Parkinsons, diabetes and traumatic brain injury. Pentagon research chief Dr. Reggie Brothers is among the speakers."
More fuel for the fire at the #C4CT Summit in a few weeks..
Judge denies initial approval of $760 million concussion settlement- States that amount is insufficient
http://sports.yahoo.com/blogs/nfl-shutdown-corner/judge-denies-initial-approval-of--765-million-concussion-settlement-180236255.html
Just for fun, can someone start a conversation about how MJFF "disavowed" Amarantus again....;)
It looks like there was an inconsistent allotment of 40 min for the next presenter, Anavex. Let's see if it starts at 12:10...
You beat me to it! Good dd predicted this months ago... Nice dot connecting zoom..
Fun to look back on this stream of "dot connecting" from several months ago when good dd speculated of the recent news..
I believe that this is a new posting from Dr. Urano's blog regarding MANF in his studies..Posted this morning.
http://wolframsyndrome.blogspot.com/
Strategy for developing drugs for the treatment of Wolfram syndrome - my current efforts
I have two goals for treating patients with Wolfram syndrome.
1. Halt the progression by drugs.
2. Restore damaged tissues using iPSCs cells modified by the genome editing.
As I mentioned before, we created iPSCs (induced pluripotent stem cells) using skin cells from patients with Wolfram syndrome. These cells can be differentiated into any types of cells.
I'd like to briefly summarize my efforts on goal #1 today. To discover drugs, I am currently leading three projects.
1. Looking for FDA-approved drugs that can potentially halt progression of Wolfram syndrome.
We looked for drugs that can protect cell death mediated by the leakage of calcium from the endoplasmic reticulum (ER) to the cytosol. We found four FDA approved drugs and one supplement so far. We are testing these drugs in Wolfram iPSC-derived neural progenitor cells and mouse models of Wolfram syndrome.
2. Looking for a new class of drugs that can protect cell death mediated by endoplasmic reticulum dysfunction.
We have developed a drug screening method to identify drugs that can protect cell death mediated by ER dysfunction. In collaboration with a non-profit organization, we are actively looking for a new class of drugs that can potentially halt the progression of Wolfram.
3. Testing if MANF (mesencephalic astrocyte-derived neurotrophic factor) can suppress the ER calcium leakage-mediated neuronal cell dysfunction in Wolfram iPSC-derived neural progenitor cells.
I will talk about more on MANF some other time. I thought that this was a good biomarker for Wolfram syndrome because expression of this molecule is increased by ER dysfunction. However, the increase of MANF might be an adaptive mechanisms of our cells to cope with abnormal ER function.
Excellent site to view the worldwide research being done with MANF.
http://worldwidescience.org/wws/search.html?searchMode=advanced&ssid=-3182401%3a1436b14e2e8%3a-7b5b
One area with a significant amount of positive research that we are yet to hear of is regarding Ischemia, both brain and heart. For example:
Mesencephalic astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes behavioral recovery in rats.
http://www.ncbi.nlm.nih.gov/pubmed/19399876
*Speculation* One of the undisclosed orphans may be tied to this area of research that seems forgotten in recent months....although it is still highlighted on Amarantus website.
Roche holds the copd/manf patent from this filing last week...
Great find!
"The Company may force the investors to convert their entire note, and call for the forced exercise of the warrant, in the event shares of the Company's common stock trade at or above $0.10/share for a period of 20 consecutive trading days, subject to customary equity conditions. The investors agreed to 'no shorting' for a period of 12 months." Per Sept 4th PR
Above .10 for 20 "consecutive trading days." This will take significant news, not just anticipation of news or blog posting. IMO, when those shares are able to be released there will plenty of meat on the bone to offset their impact....if those investors even chose to sell at that time.
Welcome back michele. Always enjoyed your input..
Agreed. We've seen it so many times....Shorts will continue their efforts to beat it down. I'm sure that whatever losses they sustain from the eventual lift-off will have been generously absorbed by the gains from their shorting efforts over the last several months.
Regardless, news today is just one more step towards bringing MANF to market and creating the cash flows to really move the stock in a sustainable uptrend....or perhaps a partnership deal with enough $$ to really consider.